69,202 Shares in LeMaitre Vascular, Inc. $LMAT Bought by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 69,202 shares of the medical instruments supplier’s stock, valued at approximately $6,056,000. Tudor Investment Corp ET AL owned approximately 0.30% of LeMaitre Vascular at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. acquired a new stake in shares of LeMaitre Vascular in the third quarter valued at about $799,000. Advisory Services Network LLC acquired a new position in LeMaitre Vascular during the third quarter valued at approximately $98,000. PharVision Advisers LLC bought a new position in LeMaitre Vascular in the third quarter valued at approximately $355,000. Verition Fund Management LLC grew its stake in LeMaitre Vascular by 136.2% in the third quarter. Verition Fund Management LLC now owns 16,907 shares of the medical instruments supplier’s stock valued at $1,480,000 after purchasing an additional 9,750 shares in the last quarter. Finally, Prosperity Wealth Management Inc. acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth approximately $932,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on LMAT shares. Weiss Ratings raised LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Roth Mkm reissued a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Citizens Jmp upped their target price on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Barrington Research lifted their price target on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $105.80.

LeMaitre Vascular Stock Up 2.0%

LMAT stock opened at $109.99 on Wednesday. The business’s fifty day moving average price is $95.58 and its two-hundred day moving average price is $89.79. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of 43.82, a PEG ratio of 3.11 and a beta of 0.66. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $115.33. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The business had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. During the same period in the prior year, the company posted $0.49 earnings per share. LeMaitre Vascular’s revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be issued a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. LeMaitre Vascular’s payout ratio is 39.84%.

Insider Activity

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 55,930 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the transaction, the chief executive officer owned 1,476,500 shares in the company, valued at $159,181,465. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David B. Roberts sold 8,464 shares of LeMaitre Vascular stock in a transaction on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the transaction, the director directly owned 17,979 shares of the company’s stock, valued at $1,920,157.20. This represents a 32.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 215,438 shares of company stock worth $23,062,911. Corporate insiders own 9.50% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.